PMID- 32538273
OWN - NLM
STAT- MEDLINE
DCOM- 20210601
LR  - 20210601
IS  - 1933-6926 (Electronic)
IS  - 1933-6918 (Print)
IS  - 1933-6918 (Linking)
VI  - 14
IP  - 1
DP  - 2020 Dec
TI  - The anti-cancer properties of heparin and its derivatives: a review and prospect.
PG  - 118-128
LID - 10.1080/19336918.2020.1767489 [doi]
AB  - Heparin, including unfractionated heparin (UFH), low-molecular-weight heparin 
      (LMWH) and heparin derivatives, are commonly used in venous thromboembolism 
      treatment and reportedly have beneficial effects on cancer survival. Heparin can 
      affect the proliferation, adhesion, angiogenesis, migration and invasion of 
      cancer cells via multiple mechanisms. The main mechanisms involve inhibition of 
      heparanase, P-/L-selectin, angiogenesis, and interference with the CXCL12-CXCR4 
      axis. Here we summarize the current experimental evidence regarding the 
      anti-cancer role of heparin and its derivatives, and conclude that there is 
      evidence to support heparin's role in inhibiting cancer progression, making it a 
      promising anti-cancer agent.
FAU - Ma, Sai-Nan
AU  - Ma SN
AD  - Department of General Surgery, The First Affiliated Hospital of Nanjing Medical 
      University , Nanjing, P.R. China.
AD  - Department of Oncology, The Affiliated Suqian Hospital of Xuzhou Medical 
      University , Suqian, P.R.China.
FAU - Mao, Zhi-Xiang
AU  - Mao ZX
AD  - Department of Oncology, Affiliated Hospital of Xuzhou Medical University , 
      Xuzhou, P.R. China.
FAU - Wu, Yang
AU  - Wu Y
AD  - Core Facility, The First Af fi liated Hospital of Nanjing Medical University , 
      Nanjing, P.R. China.
FAU - Liang, Ming-Xing
AU  - Liang MX
AD  - Department of General Surgery, The First Affiliated Hospital of Nanjing Medical 
      University , Nanjing, P.R. China.
FAU - Wang, Dan-Dan
AU  - Wang DD
AD  - Department of General Surgery, The First Affiliated Hospital of Nanjing Medical 
      University , Nanjing, P.R. China.
FAU - Chen, Xiu
AU  - Chen X
AD  - Department of General Surgery, The First Affiliated Hospital of Nanjing Medical 
      University , Nanjing, P.R. China.
FAU - Chang, Ping-An
AU  - Chang PA
AD  - Urinary Surgery, Dongtai People's Hospital , Dongtai, P.R. China.
FAU - Zhang, Wei
AU  - Zhang W
AD  - Department of General Surgery, The First Affiliated Hospital of Nanjing Medical 
      University , Nanjing, P.R. China.
FAU - Tang, Jin-Hai
AU  - Tang JH
AUID- ORCID: 0000-0003-2016-4216
AD  - Department of General Surgery, The First Affiliated Hospital of Nanjing Medical 
      University , Nanjing, P.R. China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Cell Adh Migr
JT  - Cell adhesion & migration
JID - 101469464
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antineoplastic Agents)
RN  - 9005-49-6 (Heparin)
RN  - EC 3.2.1.- (heparanase)
RN  - EC 3.2.1.31 (Glucuronidase)
SB  - IM
MH  - Angiogenesis Inhibitors/pharmacology
MH  - Animals
MH  - Antineoplastic Agents/chemistry/*pharmacology
MH  - Glucuronidase/antagonists & inhibitors/metabolism
MH  - Heparin/chemistry/*pharmacology
MH  - Humans
MH  - Lymphatic Vessels/drug effects
MH  - Neoplastic Stem Cells/drug effects/metabolism
PMC - PMC7513850
OTO - NOTNLM
OT  - Heparin
OT  - cancer
OT  - heparin derivatives
OT  - low-molecular-weight heparin
OT  - metastasis
COIS- The author reports no conflicts of interest in this work.
EDAT- 2020/06/17 06:00
MHDA- 2021/06/02 06:00
PMCR- 2020/06/14
CRDT- 2020/06/16 06:00
PHST- 2020/06/16 06:00 [entrez]
PHST- 2020/06/17 06:00 [pubmed]
PHST- 2021/06/02 06:00 [medline]
PHST- 2020/06/14 00:00 [pmc-release]
AID - 1767489 [pii]
AID - 10.1080/19336918.2020.1767489 [doi]
PST - ppublish
SO  - Cell Adh Migr. 2020 Dec;14(1):118-128. doi: 10.1080/19336918.2020.1767489.